Abstract:Background Ghrelin ( GHRL ) is a pivotal peptide regulator of food intake, energy balance, and body mass. Weight gain (WG) is a common side effect of the atypical antipsychotics (AAPs) used to treat schizophrenia (SZ). Ghrelin polymorphisms have been associated with pathogenic variations in plasma lipid concentrations, blood pressure, plasma glucose, and body mass index (BMI). However, it is unclear whether GHRL polymorphisms are associated with WG due to AAPs. Furthermore, there is no evidence of an association between GHRL polymorphisms and SZ or the therapeutic response to AAPs. We explored these potential associations by genotyping GHRL alleles in SZ patients and controls. We also examined the relation between these SNPs and changes in metabolic indices during AAP treatment in SZ subgroups distinguished by high or low therapeutic response. Methods Four SNPs (Leu72Met, -501A/C, -604 G/A, and -1062 G > C) were genotyped in 634 schizophrenia patients and 606 control subjects. Results There were no significant differences in allele frequencies, genotype distributions, or the distributions of two SNP haplotypes between SZ patients and healthy controls ( P > 0.05). There was also no significant difference in symptom reduction between genotypes after 8 weeks of AAP treatment as measured by positive and negative symptom scale scores (PANSS). However, the -604 G/A polymorphism was associated with a greater BMI increase in response to AAP administration in both APP responders and non-responders as distinguished by PANSS score reduction ( P < 0.001). There were also significant differences in WG when the responder group was further subdivided according to the specific AAP prescribed ( P < 0.05). Conclusions These four GHRL gene SNPs were not associated with SZ in this Chinese Han population. The -604 G/A polymorphism was associated with significant BW and BMI increases during AAP treatment. Patients exhibiting higher WG showed greater improvements in positive and negative symptoms than patients exhibiting lower weight gain or weight loss.

The positive association between antipsychotic-induced weight gain and therapeutic response: new biotypes of schizophrenia

Factors associated with weight gain during six-month olanzapine therapy

Genome-Wide Association Study Suggested Theptprdpolymorphisms Were Associated with Weight Gain Effects of Atypical Antipsychotic Medications

Genome-wide association study implicates lipid pathway dysfunction in antipsychotic-induced weight gain: multi-ancestry validation

TOX and ADIPOQ Gene Polymorphisms Are Associated with Antipsychotic-Induced Weight Gain in Han Chinese

Relationship of Antipsychotic Drug-Induced Weight Gain with the Polymorphism of Dopamine D2 Receptor Gene and Treatment Response in Schizophrenic Patients

No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response.

Weight Gain, Schizophrenia and Antipsychotics: New Findings from Animal Model and Pharmacogenomic Studies

Association of A2BP1 Gene Polymorphism with Olanzapine Induced Bodyweight Gain

A2BP1 Gene Polymorphisms Association with Olanzapine-Induced Weight Gain.

Associations between antipsychotics-induced weight gain and brain networks of impulsivity

Association between Ghrelin gene (GHRL) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patients

Gut Microbiome Profiles May Be Related to Atypical Antipsychotic Associated Overweight in Asian Children with Psychiatric Disorder: a Preliminary Study.

Multi-omics analysis reveals the impact of gut microbiota on antipsychotic-induced weight gain in schizophrenia

Gut Microbiome Profiles Are Related to Atypical Antipsychotic Associated Overweight in Asian Children with Psychiatric Disorder

Functional Magnetic Resonance Imaging in a Single Schizophrenia Patient with Voluntary Control over Auditory Verbal Hallucinations

[Association of -2548G/A Functional Polymorphism in the Promoter Region of Leptin Gene with Antipsychotic Agent-Induced Weight Gain].

Pharmacogenetic Study of Antipsychotic-Induced Lipid and BMI Changes in Chinese Schizophrenia Patients: A Genome-Wide Association Study

Leptin -2548G/a Gene Polymorphism in Association with Antipsychotic-Induced Weight Gain: a Meta-Analysis Study.

[No Association of -1438G/A Polymorphism in Promoter Region of 5-HT2A Receptor Gene with Antipsychotic Agent-Induced Weight Gain].

Relationship between functional connectivity and weight-gain risk of antipsychotics in schizophrenia